There is no product in the shopping cart, buy it!
Native glycosylation pathways have been discovered in certain bacterial species. Pgl from the bacterium Campylobacter jejuni is the first characterized N-glycosylation pathway. In this pathway, undecaprenyl phosphate lipid (Und-PP)-linked glycans are transferred by oligosaccharyltransferase (OST) known as PglB. PglB is a single-subunit integral membrane protein that shares significant sequence similarity with the catalytic subunit of the eukaryotic OST, which is referred to as STT3.
Bacterial O-linked glycosylation pathways share similarities with the N-linked pathways. Specific bacteria like Neisseria meningitidis and Neisseria gonorrhoeae utilize O-glycosylation to modify their pilins by two distinct OSTs, PglL and PglO, respectively. The key distinction from eukaryote glycosylation lies in the mode of glycan transfer, where the OST transfers the entire glycan in a single unit from the Und-PP carrier directly onto target proteins.
Fig.1 pgl pathway in Campylobacter jejuni.1
Since the initial discovery of N-glycosylation in bacteria, glycoengineering in bacterial hosts for the production of human therapeutics has undergone significant evolution. To obtain glycoprotein with tailored glycan structures, Creative Biolabs has developed various bacteria glycoengineering services, especially in Escherichia coli, based on advanced techniques for Genetic Glycoengineering. Our strategies primarily include the introduction of heterologous glycosylation pathways into bacteria, such as genes for glycan synthesis, transporters, glycosidases, and glycosyltransferases, aiming to establish novel pathways for bottom-up synthesis of both N- and O-linked glycosylation.
N-Linked Glycoengineering in Bacteria
We generate N-linked glycoproteins by transferring the Pgl glycosylation pathway into bacteria like E. coli. And multiple enzymes have been introduced to obtain fully humanized glycoproteins.
O-Linked Glycoengineering in Bacteria
Based on native PglL/O paradigm, we engineer human-like O-glycosylation pathways into bacteria, enabling precise and efficient site-specific O-glycosylation of human glycoproteins.
Glycoengineered bacterial species have gained widespread use for the production of vaccines and therapeutic glycoproteins due to cost reduction, streamlined bioprocessing, and enhanced customization. Additionally, bacteria can achieve higher product titers and reduced risk of viral contamination. In conclusion, these advantages render bacterial systems an appealing platform for glycoprotein expression after glycoengineering.
Technology: Glycoengineering in E. coli
Journal: Nature Chemical Biology
IF: 16.284
Published: 2010
Results: A novel method has been developed for producing homogenous eukaryotic N-glycoproteins. This method entails modifying the glycosylation machinery of Campylobacter jejuni and transferring it to E. coli to express glycosylated proteins with the GlcNAc-Asn linkage. Subsequently, the glycans are trimmed and restructured in vitro through enzymatic transglycosylation. This approach offers a potentially versatile platform for generating eukaryotic N-glycoproteins.
Fig.2 Glycosylation engineering in E. coli.2
Glycoengineering in bacteria is an active area of research and development. Creative Biolabs has pioneered the services in bacteria glycoengineering designed for the production of glycoproteins with customized glycan structures. If you have any requirements in bacteria glycoengineering, please feel free to contact us for more detailed information.
References